9999999997-19-004113.txt : 20190509 9999999997-19-004113.hdr.sgml : 20190509 20190509095225 ACCESSION NUMBER: 9999999997-19-004113 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190509 DATE AS OF CHANGE: 20190509 ACTION DATE: 20190509 RECEIVED DATE: 20190509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AGENUS INC CENTRAL INDEX KEY: 0001098972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061562417 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 000-29089 FILM NUMBER: 19809140 BUSINESS ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-674-4410 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: ANTIGENICS INC /DE/ DATE OF NAME CHANGE: 19991115 CT ORDER 1 filename1.pdf begin 644 filename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